Disease Overview
Why Multiple Sclerosis DMTs Demand Specialized BRA
With over 20 approved disease-modifying therapies spanning injectable interferons, oral small molecules, and high-efficacy infusions, MS presents one of the most complex benefit-risk landscapes in neurology. Each mechanism carries unique safety signals from opportunistic infections to cardiac events, requiring therapy-specific BRA frameworks across relapsing and progressive disease.
PML Risk with Targeted Immunosuppression
Natalizumab (AFFIRM, SENTINEL) carries a risk of progressive multifocal leukoencephalopathy (PML) caused by JC virus reactivation, with incidence reaching 1 in 80 in anti-JCV antibody-positive patients with prolonged treatment. Extended interval dosing has reduced but not eliminated this risk. Anti-CD20 therapies (ocrelizumab, ofatumumab) carry a lower but emerging PML signal requiring ongoing vigilance in the post-marketing setting.
Infection Risk with B-Cell Depletion
Ocrelizumab (OPERA I/II, ORATORIO) and ofatumumab (ASCLEPIOS I/II) achieve sustained B-cell depletion, leading to hypogammaglobulinemia in 5-10% of patients over time. This results in increased rates of serious infections, attenuated vaccine responses, and emerging signals for opportunistic infections. Long-term immunosuppression monitoring, including immunoglobulin levels and infection surveillance, is critical for benefit-risk assessment.
Cardiac and Hepatic Monitoring Burdens
S1P receptor modulators require first-dose cardiac monitoring due to transient bradycardia and AV conduction delays. Fingolimod requires 6-hour first-dose observation; siponimod (EXPAND) has a 5-day dose titration protocol. Additionally, hepatotoxicity signals with ozanimod and siponimod, and macular edema risk across the class, create multi-organ monitoring requirements that complicate real-world benefit-risk and adherence profiles.
Platform Capabilities
How ArcaScience Addresses Multiple Sclerosis BRA
Our modules are configured with MS disease-modifying therapy data, infection and PML detection models, cardiac safety algorithms for S1P modulators, and regulatory templates for neurology submissions.
MS DMT Clinical Data
2,400+ MS clinical trials including OPERA I/II, ASCLEPIOS I/II, EXPAND, AFFIRM, TRANSFORMS, and DEFINE/CONFIRM datasets. Comprehensive safety databases covering anti-CD20 monoclonals, S1P modulators, fumarates, teriflunomide, cladribine, and alemtuzumab with therapy-specific adverse event taxonomies. Integrated JCV antibody index data and PML case registries from 15+ years of post-marketing surveillance.
Explore Data Engine →MS-Specific AI Safety Models
AI models for PML risk stratification using JCV antibody index, treatment duration, and prior immunosuppression. Infection signal detection for anti-CD20-associated hypogammaglobulinemia and opportunistic infections. Cardiac safety monitoring algorithms for S1P first-dose events. Comparative efficacy-safety modeling across all 20+ approved DMTs for relapsing and progressive MS, including emerging BTK inhibitors (tolebrutinib, fenebrutinib, remibrutinib).
Explore AI Models →Neurology Regulatory Outputs
PSURs with dedicated sections for PML surveillance, infection monitoring, and long-term immunosuppression outcomes. RMPs incorporating JCV testing protocols, first-dose cardiac monitoring requirements, and pregnancy risk management plans. Comparative BRA documents supporting treatment sequencing decisions, and post-marketing commitment reports aligned with FDA REMS programs and EMA risk minimization measures for MS DMTs.
Explore Outputs →MS Intelligence
Platform Performance in Multiple Sclerosis
MS safety data points tracked
Faster PML signal detection vs. traditional methods
DMT-specific safety models deployed
MS regulatory submissions supported
Case Evidence — Multiple Sclerosis
Long-Term Infection Risk Monitoring for Anti-CD20 Therapy
Challenge
A pharma company required comprehensive post-marketing benefit-risk evaluation for their anti-CD20 monoclonal antibody in relapsing MS, with specific focus on cumulative hypogammaglobulinemia, serious infection rates beyond year 5 of treatment, and attenuated vaccine responses in an immunosuppressed population during respiratory virus seasons.
Result
ArcaScience's AI models identified an IgG decline trajectory that predicted serious infection risk 3.2x earlier than standard threshold-based monitoring, enabling proactive immunoglobulin level-guided dosing recommendations. The platform also quantified vaccine response attenuation rates, supporting updated RMP guidance on vaccination timing relative to treatment cycles.
Earlier infection risk prediction
Reduction in unplanned treatment discontinuations
VP of Neuroscience Pharmacovigilance
Top-10 Pharma Company
Frequently Asked Questions